Jennifer focuses her practice on the defense of pharmaceutical and medical device manufacturers engaged in product liability litigation. She plays an instrumental role in analyzing complex legal issues at various stages of litigation—from initial claim evaluation through dispositive motion practice. Jennifer also advises clients on issues governed by the Food and Drug Administration, including product labeling, recalls, regulatory compliance, and risk evaluation and management. In addition, Jennifer has defended food and drug manufacturers in consumer class actions. She has worked on legal issues involving a wide variety of products, including prescription medications, animal health products and implanted medical devices.
Jennifer has served on Shook’s Diversity and Inclusion Committee, and she continues to participate in the firm’s efforts to recruit diverse talent. She is active with the Asian American Bar Association of Kansas City and served as the organization's president. In 2013, Jennifer served on the host committee for the National Asian Pacific American Bar Association Annual Convention.
Jennifer's experience includes:
Litigation: developing strategies to secure favorable results for clients, investigating and obtaining key evidence through discovery, drafting successful dispositive motions, and managing individual and consolidated cases across the country.
Risk Management: preparing pre-litigation risks assessments, advising clients on strategies for minimizing and managing risks, and crafting advantageous resolution strategies.
Regulatory: counseling clients on compliance with FDA regulations, responding to administrative actions, addressing product recall concerns, and advising manufacturers on labeling and marketing claims for products regulated by FDA.
For several years, Jennifer has co-authored chapters in Food and Drug Law Institute’s Top 20 Food and Drug Cases, an annual compendium of the most important cases in those fields. Subjects have included:
- an appellate court decision discussing a direct-to-consumer exception to the learned intermediary doctrine for prescription drugs or devices (Centocor, Inc. v. Hamilton);
- a Seventh Circuit decision clarifying fraudulent joinder in a case involving oral contraceptives (Walton v. Bayer Corp.);
- a record year of settlements in the pharmaceutical industry on issues related to marketing, drug pricing, kickbacks and deceptive advertising;
- a case centered on the labeling of organic cosmetics under the Organic Foods Production Act (Dronkers v. Kiss My Face LLC); and
- a summary of significant FDA actions exploring the agency's role in developing relevant policies and guidance.
Steve Thomas & Jennifer Stonecipher Hill, Conte Reeling in the Wake of California Supreme Court Decision, 20:2 RX for the Defense, July 2012.
Madeleine McDonough & Jennifer Stonecipher Hill, Learning from Our Neighbors about Regulation of Biosimilar Drugs, The National Law Journal's Food and Drug Practice: A Special Report, March 14, 2011.
PLIVA, Inc. v. Mensing: Implications for Generic and Name-Brand Manufacturers, SHB In-House Presentation (November 2011).
Menu Labeling for Restaurants: FDA’s Proposed Rule Is Served and on the Table, Hot Topics in Agribusiness & Food Safety, CLE Webcast (May 2011).